Company: GNMSF
Filing Date: 2025-02-12
Form Type: 20-F
Source: 0001558370-25-000846
Chunk: 40

Company: GENMAB A/S
Filing Date: 2025-02-12
Form: 20-F
Item: Item 4I
Chunk 40
---
, the antibody pair used to create amivantamab was selected. J&J is responsible for the development and commercialization of amivantamab. Amivantamab, marketed as RYBREVANT, is approved in certain territories including the U.S., Europe and other markets for the treatment of certain adult patients with NSCLC with EGFR exon 20 insertion mutations.
Teclistamab
In July 2012, and as amended in December 2013, Genmab entered into a collaboration with J&J to create and develop bispecific antibodies using Genmab’s DuoBody technology platform. One of the products subsequently created, discovered and developed by J&J is teclistamab, a bispecific antibody that targets CD3, which is expressed on T-cells and B-cell maturation antigen (“BCMA”), which is expressed on mature B lymphocytes. J&J is responsible for the development and commercialization of teclistamab. Teclistamab, marketed as TECVAYLI, is approved in certain territories including the U.S., Europe and other markets for the treatment of certain adult patients with R/R MM.
Talquetamab
In July 2012, and as amended in December 2013, Genmab entered into a collaboration with J&J to create and develop bispecific antibodies using Genmab’s DuoBody technology platform. One of the products subsequently created, discovered and developed by J&J is talquetamab, a bispecific antibody that targets CD3, which is expressed on T-cells and G protein–coupled receptor, family C, group 5, member D (“GPRC5D”), an orphan receptor expressed in malignant plasma cells. J&J is responsible for the development and commercialization of talquetamab. Talquetamab, marketed as TALVEY, is approved in certain territories including the U.S., Europe and other markets for the treatment of certain adult patients with R/R MM.
Ofatumumab
Ofatumumab is a human monoclonal antibody that targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops. Genmab used technology licensed from Medarex to generate the CD20 antibody. Ofatumumab, marketed as Kesimpta, is approved in territories including the U.S., Europe and Japan for the treatment of certain adult patients with RMS. Ofatumumab is the first B-cell therapy that can be self